Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 165.72 8.3 (5.27%) Market Cap: 20.96 Bil Enterprise Value: 19.89 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 67/100

Alnylam Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2022 / 03:10PM GMT
Release Date Price: $206.59 (-2.55%)
Andrew Galler

Great. I'm Andrew Galler, one of the biotech analysts here at Morgan Stanley, and I'm pleased to be joined by Alnylam. Joining bench from the company, we have Akshay Vaishnaw, the President. And we say Rena Denoncourt who is VP and head of the TTR franchise.

Before we begin, I would like to read the disclosure statement. For important disclosures, please see the Morgan Stanley Research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

So first of all, thank you both for joining us today.

Rena N. Denoncourt
Alnylam Pharmaceuticals, Inc. - VP & TTR Franchise Lead

Thanks for having us.

Andrew Galler

Great. I see we're out of time. So thank you so much for joining us today.

Akshay K. Vaishnaw
Alnylam Pharmaceuticals, Inc. - President

Thank you Andrew.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot